Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 13,366 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Intracranial CNS Disorder Clear all

Conditions: Migraine Disorders
Interventions: Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Amantadine Hydrochloride, USP, Placebo; Drug
Lead sponsor: David C. Henderson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Tumor
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Inflammation, Brain
Interventions: No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma Multiforme, Anaplastic Glioma
Interventions: Temodar and O6-Benzylguanine (BG); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain Tumors
Interventions: Presurgical MRI, functional MRI (fMRI) of the brain; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Traumatic Brain Injury, Severe Traumatic Brain Injury, Disorders of Consciousness Due to Severe Brain Injury, Coma, Traumatic
Interventions: Dual-Site Transcutaneous Auricular Nerve Stimulation (taVNS + taTNS); Device
Lead sponsor: Sima Mofakham; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Alzheimer's Disease, Dementia
Interventions: Placebo, Medication Therapy Management (MTM), Scopolamine patch; Other · Drug
Lead sponsor: Daniela Moga; Other
Eligibility: 65 Years to 101 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Stroke, Healthy
Interventions: Assisted Motion with Enhanced Sensation training; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Solid Tumors, CNS Tumors
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Polypharmacy, Dementia
Interventions: Educational nudge intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Stroke, Ischemic, Stroke Hemorrhagic, Spastic Hemiparesis
Interventions: Contralateral C7 root transfer for the treatment of spastic hemiparesis.; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Sickle Cell Disease, Cerebral Stroke
Interventions: Carbon Dioxide; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer Disease
Interventions: Tricaprilin; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Brain Tumor
Interventions: Intra-operative Ommaya Reservoir placement; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions: [123I]CLINDE; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 30 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
Interventions: Tissue specimen collection, MRI; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 70 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1997
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polypharmacy, Dementia, Quality of Life
Interventions: Shed-MEDS deprescribing intervention; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 65 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Parkinson's Disease
Interventions: Detailed motor testing, including FoG, in PD subjects; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson Disease, Essential Tremor
Interventions: Apomorphine Injectable Solution, Subcortical Stimulation; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dementia, Dementia Alzheimers, Dementia, Vascular, Dementia, Mixed
Interventions: No interventions; Other
Lead sponsor: University of Michigan; Other
Eligibility: 65 Years and older
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Corpus Christi, Texas

Conditions: Tourette Syndrome
Interventions: Modified Atkins diet; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Interventions: LITT + Pembrolizumab; Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma, Medulloblastoma, Paraganglioma, Pituitary Adenoma
Interventions: Ga68-DOTATATE-PET/MRI; Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2038
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

BTC Neuropsychological Database

Control of Leukocyte Function

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma

Presurgical Planning With Functional MRI (fMRI) Mapping of Motor Cortex in Patients With Cerebral Tumors

Vagus Nerve Stimulation in Patients in Comatose State

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

Effects of Vibration on Motor Function of Survivors of Chronic Stroke

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD)

Utility of CC7 Transfer in Stroke Subtypes

Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

Ommaya Reservoir Placement for Brain Tumor Biomarker Access

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

Motor Network Physiology

Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)

Pilot Study of the Modified Atkins Diet for Tourette Syndrome

LITT and Pembrolizumab in Recurrent Brain Metastasis

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.